TNFRSF18 antibody (PE)

Catalog No. ABIN2663407

The Mouse Monoclonal anti-TNFRSF18 antibody is suitable to detect TNFRSF18 in samples from Human. It has been validated for BCA.

Quick Overview for TNFRSF18 antibody (PE) (ABIN2663407)

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFRSF18 antibody is conjugated to PE

Application: Biochemical Assay (BCA)

Clone: 621

Product Details anti-TNFRSF18 Antibody (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TNFRSF18

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Alternative Name: CD357

Background: GITR (glucocorticoid-induced TNF receptor family-regulated gene) is a 25 kD TNF receptor superfamily member (also known as AITR and TNFRSF18). GITR is expressed on activated lymphocytes and is upregulated by T cell receptor engagement. The cytoplasmic domain of GITR is homologous to CD40, 4-1BB and CD27 and has been shown to interact with TRAF 1-3, but not TRAF 5 or 6. GITR signaling has been shown to regulate T cell proliferation and TCR-mediated apoptosis, and to break immunological self-tolerance. GITR binds GITRL and is involved in the development of regulatory T cells and to regulate the activity of Th1 subsets.

Pathways: Cancer Immune Checkpoints